Effect of Crataegus Monogyna in hypertension and associated sleep disorder

The clinical trial of the effect of crataegus monogyna on hypertension and associated sleep disorders

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180225038859N1

Enrollment

Registered

2018-05-26

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: Dry extract of Crataegus Monogyna with a concentration of 10% relative to 100 gr of the plant, has been standardized 250mg per capsule at the school of pharmacy of

Eligibility

Sex/Gender

All

Age

35 Years to 60 Years

Inclusion criteria

Inclusion criteria: Hypertensive patient that they didn't respond to medical treatment

Exclusion criteria

Exclusion criteria: Pregnancy Breast feeding Malignancy Sever hypertension Chronic Inflamatory diseas Renal failure Sever liver disease Acute infectious disease Secondary hypertension Age less than 35 and older than 60 Taking digoxin Arryhthmia

Design outcomes

Primary

Measure	Time frame
Quality of sleep in the Pittsburgh Questionnaire. Timepoint: Measure the quality of sleep at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Pittsburgh sleep quality questionnaire in patients with hypertension.;Systolic blood pressure. Timepoint: Measure the Blood Pressure at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Pressure Device.	—

Measure

Time frame

Quality of sleep in the Pittsburgh Questionnaire. Timepoint: Measure the quality of sleep at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Pittsburgh sleep quality questionnaire in patients with hypertension.;Systolic blood pressure. Timepoint: Measure the Blood Pressure at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Pressure Device.

—

Secondary

Measure	Time frame
Fasting blood sugar test. Timepoint: Measure the FBS at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Blood Urea Nitrogen. Timepoint: Measure the BUN at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Hemoglobin. Timepoint: Measure the Hb at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Creatinine. Timepoint: Measure the Cr at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;ALT and AST. Timepoint: Measure the ALT and ASTbat the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Triglyceride. Timepoint: Measure the TG at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.	—

Measure

Time frame

Fasting blood sugar test. Timepoint: Measure the FBS at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Blood Urea Nitrogen. Timepoint: Measure the BUN at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Hemoglobin. Timepoint: Measure the Hb at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Creatinine. Timepoint: Measure the Cr at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;ALT and AST. Timepoint: Measure the ALT and ASTbat the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.;Triglyceride. Timepoint: Measure the TG at the beginning of study(before intervention)and two week after taking the Crataegus Monogyna. Method of measurement: Blood Test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasume Abbasi

Zanjan University of Medical Sciences

abbasi1393@zums.ac.ir+98 24 3377 0801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026